Detection of single nucleotide variants in circulating tumor DNA of patients with metastatic castration resistant prostate cancer

R
Roberto Pili, MD

Primary Investigator

J
Jessica MacLean

Primary Investigator

Recruiting
100 years and younger
All
Phase N/A
2 Locations

Brief description of study

The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.

Detailed description of study

The purpose of this study is to investigate cell-free DNA in patients with metastatic castration-resistant prostate cancer receiving therapy with abiraterone or enzalutamide.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: prostate cancer
  • Age: - 100 Years
  • Gender: All
Updated on 01 Aug 2024. Study ID: 1706003129 (IUSCC-0634)

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center